Practice Management
The Food and Drug Administration (FDA) has approved oral remibrutinib, a new drug product, as a second-line treatment for chronic spontaneous urticaria (CSU). Remibrutinib has a unique mechanism to block the activity of Bruton’s tyrosine kinase (BTK), stopping a key pathway of the immune response in CSU, according to a manufacturer press release. The condition is thought to be caused by immune dysregulation, and it is believed that once activated, BTK leads to the release …
Read More
The Food and Drug Administration (FDA) has approved the combination sulopenem etzadroxil and probenecid, an oral antibiotic, to treat bacterial urinary tract infections (UTI) in adult women caused by Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis. Manufacturer Iterum Therapeutics anticipates a commercial launch for the drug, branded as Orlynvah, in 2025, according to Reuters. The oral drug is taken twice daily for 5 days and can be used to treat uncomplicated UTIs in women who …
Read More